Navigation Links
Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
Date:10/18/2010

0;27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.  These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.  The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness, including increases in the LIBOR rates on our variable-rate indebtedness above the applicable floor amounts; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facilities that produce our products or production or regulatory problems with either third party manufacturers or API suppliers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regu
'/>"/>
SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
2. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
3. Warner Chilcott Announces FDA Approval of Next Generation Actonel
4. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
5. Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex®
6. Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
7. Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to Acquire U.S. Rights to Enablex®
8. Warner Chilcott to Present at UBS Global Life Sciences Conference
9. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
10. Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance
11. Warner Chilcott Announces Earnings Release Date and Conference Call for Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...  Champions Oncology, Inc. (OTC: CSBR), engaged in the ... the development and use of oncology drugs, today announced ... 2015. Fourth Quarter and Recent Business Highlights: ... prior year period result , Procured a quarterly ... Joel Ackerman, Champions Oncology CEO, stated, "The end of ...
(Date:7/28/2015)... 28, 2015  Roche (SIX: RO, ROG; OTCQX: ... for Clinical Chemistry (AACC) 2015 Clinical Lab Expo ... and a unique educational initiative that demonstrates how ... value of the laboratory. The new ... empower laboratories and the people within them through ...
(Date:7/28/2015)... and HOUSTON, TX , July 28, 2015 ... EPIX ) is pleased to announce that it has received ... commence trading on the Toronto Stock Exchange (the "TSX"). The ... trading on Tuesday, July 28, 2015 under the trading symbol ... TSX Venture Exchange. About ESSA Pharma Inc. ...
Breaking Medicine Technology:Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 3Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 4Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 5Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 6Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 7Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 8Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 9Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 10Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 11Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 2Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 3Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 4ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3
... Inc. (NASDAQ: ARNA ) today announced that Robert ... Vice President, Finance and Chief Financial Officer. Mr. Hoffman served ... before departing in March to work for a private biopharmaceutical ... been a key contributor to Arena," said Jack Lief, Arena,s ...
... 2011 / PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: ... commercializing products targeting the extracellular matrix , today ... 2011 Life Sciences Conference in New York. The presentation ... EDT (6:10 a.m. PDT). To listen to the live ...
Cached Medicine Technology:Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 2Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 3Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17 2
(Date:7/28/2015)... Boston, MA (PRWEB) , ... July 28, 2015 , ... ... developing cancer. One reason is that cancer, heart attack, and stroke are treatable, but ... One thing individuals can do is to take part in a clinical trial, reports ...
(Date:7/28/2015)... ... July 28, 2015 , ... The ... Attack, Sudden Death, or Angina), many of whom are missed by conventional evaluation ... individuals with active yet undetected sub-clinical disease, who are at risk of experiencing ...
(Date:7/28/2015)... ... July 28, 2015 , ... For more than two ... based its selection process on the foundation of peer nominations. Physicians nominate other ... any area of medicine and in any part of the country. Physicians cannot ...
(Date:7/28/2015)... ... July 28, 2015 , ... One ... including Runner’s World Magazine, is plantar fasciitis . Zensah, the Miami-based compression ... Designed by a professional athletic trainer, the Zensah Ankle Support’s primary benefits include ...
(Date:7/28/2015)... ... , ... Nurses across all settings increasingly provide care to people with mental ... mental health services (SAMHSA, 2013) and the implementation of the Affordable Care Act is ... the largest workforces who provide care to persons with mental health disorders. Providing this ...
Breaking Medicine News(10 mins):Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 3Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 4
... being circulated in South Asia for various ailments like malaria, ... a British doctor in Laotian capital, Vientiane, the drugs have ... find out. ,World Health Organization states that majority ... been treated with the original drug. They also add that ...
... the makers of ADHD drugs to indicate the contra indications ... cardiovascular risks. ,Dr. Steven Galson, director of the ... these drugs are immensely useful in treating patients with ADHD, ... He also said that FDA is working in tandem ...
... of your wedding celebration. The world-renowned research and care center ... save lives of cancer patients. Couples getting married are encouraged ... Jimmy Fund. Dana-Farber treats both children and adults, and is ... ,A package of 10 table cards, gift cards, or ...
... about that shared experience are likely more satisfied with ... of experience to draw on, according to research by ... ,The study, conducted by Doris G. Bazzini and three ... issue of the journal Motivation and Emotion. ...
... Mukesh Haikerwal, today congratulated the Victorian Government on introducing ... child carers are trained in handling potentially deadly severe ... anaphylaxis program to be implemented nationally. ... to protect the children who suffer from severe allergies, ...
... who become impotent after prostate cancer surgery may find reprieve ... penis,// which assists in restoring the lost erectile function, according ... came to light after a study of nearly 44 patient ... function, following its loss after treatment for prostate cancer. ...
Cached Medicine News:Health News:Researcher Studies Benefits of Reminiscing About Laughter 2Health News:National Plan Needed for Severe Allergy Kids 2
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 15 mm blades allow intraocular manipulation without metal to metal contact. 16 mm lifting wings. Dull finish....
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Medicine Products: